0001567619-21-013514.txt : 20210715 0001567619-21-013514.hdr.sgml : 20210715 20210715173613 ACCESSION NUMBER: 0001567619-21-013514 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210715 FILED AS OF DATE: 20210715 DATE AS OF CHANGE: 20210715 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peppe Jennifer CENTRAL INDEX KEY: 0001861060 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40604 FILM NUMBER: 211093536 MAIL ADDRESS: STREET 1: IMAGO BIOSCIENCES, INC. STREET 2: 329 OYSTER POINT BLVD. 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Imago BioSciences, Inc. CENTRAL INDEX KEY: 0001623715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454915810 STATE OF INCORPORATION: DE FISCAL YEAR END: 1214 BUSINESS ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 904080 BUSINESS PHONE: 650 325 5156 MAIL ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 904080 3 1 doc1.xml FORM 3 X0206 3 2021-07-15 0 0001623715 Imago BioSciences, Inc. IMGO 0001861060 Peppe Jennifer C/O IMAGO BIOSCIENCES, INC. 329 OYSTER POINT BLVD, 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 148809 D Stock Option (Right to Buy) 2.19 2019-11-17 2025-11-16 Common Stock 2976 D Stock Option (Right to Buy) 2.27 2020-11-09 2026-11-08 Common Stock 2380 D Stock Option (Right to Buy) 2.52 2021-01-01 2027-03-28 Common Stock 79551 D Stock Option (Right to Buy) 1.52 2029-04-09 Common Stock 32738 D Stock Option (Right to Buy) 2.10 2030-09-09 Common Stock 59523 D Stock Option (Right to Buy) 4.20 2031-02-04 Common Stock 23809 D Reflects a 8.4-for-1 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 12, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Senior Vice President, Clinical Operations /s/ Matthew Plunkett, as Attorney-in-fact for Jennifer Peppe 2021-07-15 EX-24 2 jenniferpoa.htm
POWER OF ATTORNEY
With respect to holdings of and transactions in securities issued by Imago BioSciences, Inc. (the “Company”), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned’s true and lawful attorney-in-fact to:
1.
prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the United States Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
2.
execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
3.
do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
4.
take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-facts discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is any Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 22 day of March, 2021.

By: /s/ Jennifer Peppe
Name: Jennifer Peppe
Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

1.
Hugh Rienhoff, Jr., MD
2.
Matthew Plunkett, Ph.D.